Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
about
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancerRecurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicitiesTargeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cellsFunctional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer ActivityChemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles.Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.Polymeric micellar delivery systems in oncology.Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).Issues of ovarian cancer survivors in the USA: a literature review.Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.SN-38 active loading in poly(lactic-co-glycolic acid) nanoparticles and assessment of their anticancer properties on COLO-205 human colon adenocarcinoma cells.Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages.The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation.Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis.Liposome-loaded thermo-sensitive hydrogel for stabilization of SN-38 via intratumoral injection: optimization, characterization, and antitumor activity.Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Intermediate-dose melphalan with stem-cell support in platinum-refractory ovarian cancer.
P2860
Q28648402-F1241219-0B35-4B14-9FDE-94227027D4BCQ30444706-C42DB942-E399-4373-9AFC-0E9B8ADB3BEEQ33388089-28F9A1C3-3600-4816-99D6-D7FC331126E6Q33395064-2F46549D-A366-4890-AD6D-CDF8A2EE9515Q33415076-2E035FB2-8EAE-487A-92C7-A5B2C75F3BC4Q33419856-41D5E71B-FF66-442C-8AB1-A8657E8C493CQ33858199-FC6BDB66-068B-40CB-BF30-EFC2E9F268E0Q34484362-86A4CEC4-D41B-4466-BFD5-C88A9735CE1AQ35088311-F5362C8D-1169-4FEF-85C5-8FF445A29DB4Q35538822-660FF575-E805-4C2E-9E57-BE48C760A380Q35655672-39EDEC80-9236-45F1-B2EB-8426E293A374Q35824168-F89D7D77-0D6A-4A98-AB2C-B80F5C18B6BFQ36444444-99136460-C24E-421B-AC91-A6F568528C02Q36613525-62961A8E-4691-48C7-AE98-1FE3D08BDA84Q36900219-9C4B7F68-DC3A-4BE0-B37D-4B6EE7A0309DQ37060403-E0609562-DC3D-47EA-A5F8-4A8E2FD457ABQ37159547-F35624A8-4158-44BF-9314-A94F750BC6F0Q37319114-0E6ED9C9-4997-40C5-B00E-583CAA2E3891Q37567702-9C4C316A-0473-4F08-A61D-5BA3E4DBF735Q38121002-49CF0FDB-9367-4D8F-BC8A-03C062C162DAQ38180311-B589F3C7-56D8-4D13-9C97-6E67959EF4A2Q38834678-4E714B9A-A54B-4E41-9EB7-FE799877A458Q42223084-FA23F5D4-4C07-4EB5-9432-E0A89926F915Q43010573-884EDCA4-329F-4710-B5F8-1744037B8EDFQ46401314-879E6E94-C08D-4BFB-82A8-014B3F0701E1Q49788115-19F8C11A-775D-46D1-B980-7BA82415B469Q50092450-5F5220C4-CD31-456D-A840-B08D3CDF5B2AQ51024873-2BC90820-5737-4AB1-AE61-24515EB0509BQ52362144-3E0AB21F-F824-4D22-9ADE-37803A94C9C7Q53897263-E33A531B-F606-4457-99A5-E50966BBC63D
P2860
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Phase II trial of irinotecan i ...... n cancer or peritoneal cancer.
@en
Phase II trial of irinotecan i ...... n cancer or peritoneal cancer.
@nl
type
label
Phase II trial of irinotecan i ...... n cancer or peritoneal cancer.
@en
Phase II trial of irinotecan i ...... n cancer or peritoneal cancer.
@nl
prefLabel
Phase II trial of irinotecan i ...... n cancer or peritoneal cancer.
@en
Phase II trial of irinotecan i ...... n cancer or peritoneal cancer.
@nl
P2093
P356
P1476
Phase II trial of irinotecan i ...... an cancer or peritoneal cancer
@en
P2093
Charles Levenback
David M Gershenson
J Taylor Wharton
Jacalyn Gano
John J Kavanagh
Judith K Wolf
P304
P356
10.1200/JCO.2003.02.091
P407
P577
2003-01-01T00:00:00Z